PPD-SNBL in Japan

How We Help Expertise Asia Pacific PPD-SNBL in Japan

Local management and global-scale capabilities

The PPD™ clinical research business of Thermo Fisher Scientific has a partnership with Shin Nippon Biomedical Laboratories Ltd. (SNBL), a proven Japanese Clinical Research Organization (CRO), which provides local, on-the-ground management. This joint venture brings deep knowledge of Japanese culture and regulations, in addition to the confidence that comes from accessing the breadth and quality of services and tools you would expect from a leading global provider of CRO solutions. PPD-SNBL’s unique model demonstrates our understanding of the need for local and cultural alignment.

years of local experience

0 +

patients

0 +

running global studies

0 +

sites

0 +

clinical trials in five years

0 +

PPD-SNBL team members in 3 cities

Why PPD-SNBL in Japan?

PPD-SNBL has a long history of excellence in Japan, having partnered with more than 20 international pharmaceutical companies on over 150 studies in Japan. Our partners have recognized and provided positive evaluations related to our performance and delivery. We offer full-service capabilities and apply our strong, growing team to ensure excellence in clinical trial delivery.

High quality

PPD-SNBL has an excellent track record of providing high quality services. We operate according to ICH-GCP standards and have had no critical findings from audit agencies following multiple inspections.

Single accountability model

Accountability and decision-making stays in Japan. A single CRA manages the entire study from start up to study closure with all functional leaders in Japan reporting directly to the PPD-SNBL general manager.

Low turnover rates

Named the fifth-fastest-growing business in Japan by Randstad, PPD-SNBL has been recognized for staff retention success in a highly competitive recruiting market.

PPD SNBL: Top Pharmaceutical outsourcing services provider in APAC 2023. Awarded by Pharma Tech Outlook

PPD-SNBL is recognized as one of the Top of 10 companies that are at the forefront of providing Pharmaceutical Outsourcing services and impacting the Pharma industry in APAC 2023.

“PPD-SNBL embodies all the qualities of an ideal CRO-blending quality, speed and cost-efficiency to effectively serve the needs of its clients and contribute to the advancement of clinical research. As clinical development specialists, it provides a wide array of high-quality services ranging from monitoring all stages of clinical development to regulatory consulting and beyond.“

— Pharma Tech Outlook

PPD-SNBL provides a full range of clinical development expertise in Phase I-IV clinical capabilities to support global or local trials, including:

Project management, clinical monitoring, data management (Edc), Biostatistics, Medical Writing, Pharmacovigilance, Regulatory Affairs, Clinical Supplies, Dossier Submissions, Quality Assurance.

Consulting expertise:

NDA strategy
KOL development
Protocol development
PMDA consultation
Feasibility

Experience by therapeutic area past five years

PPD and SNBL: Hematology/Oncology: 50%. Neurology: 8%. Cardiovascular: 8%. Infectious Disease: 8%. Gastrointestinal: 7%. Endocrinology/Metabolic: 4%. Respiratory: 3%. Immunology: 3%. Ophthalmology: 2%. Dermatology: 1%. Women's Health: 1%. Musculoskeletal: 1%. Pain: 1%. Other: 4%.

Strong leadership in Japan

Yasumasa Kurioka

As the PPD-SNBL general manager, Yasumasa Kurioka takes a unique approach to leverage the global power of PPD’s vast resources, expertise and capabilities.

“Our goal is to maintain the highest standards of quality in our services to turn into the most trusted CRO in Japan.”